United States

Analyst Research Report Snapshot


Sarepta Therapeutics, Inc. (SRPT) - Financial and Strategic SWOT Analysis Review






11 Jan 2013





Companies referenced:


Available for Immediate Download

Sarepta Therapeutics, Inc. (SRPT) - Financial and Strategic SWOT Analysis Review Summary Sarepta Therapeutics, Inc. (Sarepta), formerly AVI BioPharma, Inc., is a biopharmaceutical company. It undertakes the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The company's drug development is based on phosphorodiamidate morpholino oligomer (PMO) technology platforms. The company's rare disease treatment product portfolio includes Eteplirsen, AVI-5038 and candidate for skipping of exon 45. Sarepta Therapeutics, Inc. Key Recent Developments: Nov 07, 2012: Sarepta Therapeutics Reports Revenue Of $7.6m In Q3 2012 Nov 05, 2012: Sarepta Therapeutics Appoints Sandesh Mahatme As CFO Oct 03, 2012: Sarepta Therapeutics Receives Notice From Department Of Defense For Termination Of Ebola Therapeutic Program Aug 07, 2012: Sarepta Therapeutics Reports Revenue Of $11.2m In Q2 2012 Jul 27, 2012: Sarepta Therapeutics Regains NASDAQ Compliance This comprehensive SWOT profile of Sarepta Therapeutics, Inc. provides you an in-depth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description - A detailed description of the company's operations and business divisions. - Corporate strategy - Analyst's summarization of the company's business strategy. - SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats. - Company history - Progression of key events associated with the company. - Major products and services - A list of major products, services and brands of the company. - Key competitors - A list of key competitors to the company. - Key employees - A list of the key executives of the company. - Executive biographies - A brief summary of the executives' employment history. - Key operational heads - A list of personnel heading key departments/functions. - Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities - A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Note: Some sections may be missing if data is unavailable for the company. Key benefits of buying this profile include: You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors. Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company's core strengths and we...

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.